Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Abiomed names new VP and general manager of global sales and marketing
Prior to joining Abiomed, Mr Howley spent 20 years at GE Healthcare. From 2006 to 2009, he was general manager at GE Healthcare, overseeing the Americas X-ray and
Prior to joining Abiomed, Mr Howley spent 20 years at GE Healthcare. From 2006 to 2009, he was general manager at GE Healthcare, overseeing the Americas X-ray and
Endo Pharmaceuticals, a specialty pharmaceutical company, has given notice that it is returning to Durect, a specialty pharmaceutical company, its rights in the US and Canada to develop
The company will split its US sales operations into three market segments: neurology, neurointerventional, and physician office. The neurology market includes neurologists and physical medicine and rehabilitation physicians.
Mr Celano has extensive experience in life sciences where he spent 24 years in public accounting as a partner with KPMG and Arthur Andersen holding life science leadership
For 2008, Emergent reported net income of $20.7 million, or $0.68 diluted earnings per share, compared to $22.9 million, or $0.77 diluted earnings per share for 2007. The
For full year 2008, the company reported net loss of $18.5 million, or $0.36 basic and diluted net loss per share, a 58% reduction compared to a net
For full year 2008, the company reported net loss applicable to common stock shareholders of $15.84 million, or $0.32 diluted net loss per common share, compared to a
For full year 2008, net loss was $41.6 million, or $0.64 basic and diluted net loss per share, compared to net loss of $42.2 million, or $0.96 basic
Novavax, a biopharmaceutical company, has announced encouraging results from a preclinical study of a respiratory syncytial virus vaccine candidate directed against the viral fusion protein. The virus utilizes
Nektar Therapeutics, a biopharmaceutical company, has reported positive topline results from a Phase II double-blind, randomized, placebo-controlled study of NKTR-118 in patients with opioid-induced constipation. The Phase II